Abstract: Benzodiazepine-like drugs (z-hypnotics) are the most commonly used drugs for treatment of insomnia in Norway. Zhypnotics are recommended for short-term treatment not exceeding 4 weeks. We aimed to study the use of z-hypnotics in the adult population in Norway with focus on recurrent use in new users, treatment intensity and co-medication with benzodiazepines and opioids in long-term users. Data were obtained from the Norwegian Prescription Database. New users in 2009 were followed through 2013. Recurrent z-hypnotic use was defined as new fillings at least once in each of the four 365-day follow-up periods. Age groups of 18-39, 40-64 and 65+ years were analysed separately for men and women. In 2013, 354,571 (8.9%) of the population filled at least one prescription of z-hypnotics and the prevalence was relatively stable over time. Among the 92,911 new users of z-hypnotics in 2009, 13,996 (16.8%) received z-hypnotics all four 365-day periods of follow-up. In these long-term recurrent users, the treatment intensity was high already the second year, with mean annual amounts of 199 and 169 DDDs per patient in men and women, respectively. The interquartile differences were greatest in the youngest age group. 27.9% of the long-term recurrent users of z-hypnotics used benzodiazepines the fourth year and 33.9% used opioids. The proportions with co-medication increased with level of z-hypnotic treatment intensity. Overall, many z-hypnotic users had medicines dispensed for longer periods than recommended, and co-medications with drugs that may reinforce the central depressing and intoxicating effects were common.
Benzodiazepine (BZD)-like hypnotic drugs (z-hypnotics: zolpidem, zopiclone/eszopiclone and zaleplon) were introduced in the 1990s. Even though the pharmacological properties are similar to the BZDs, the z-hypnotics were considered to be effective alternatives with better safety profiles due to their favourable pharmacokinetic profiles [1] . The shorter duration of action of z-hypnotics may reduce the risk of residual effects. However, it has been shown that use of zopiclone leads to many of the same effects as BZDs: sleepiness/drowsiness, muscle relaxation and amnesia [1] .
Non-pharmacological treatment has been considered the most effective treatment of insomnia and should be tried before initiating treatment with a hypnotic agent [2, 3] . A review article showed that even though the number of insomnia publications has increased in recent years, there are still inadequate evidence of the effectiveness and side effects [4] . Hypnotics are indicated for short-term treatment only, and a single course of treatment should not exceed 4 weeks [2, 5, 6] . There is limited information on the effectiveness of long-term use of hypnotics [7, 8] . Despite the recommendations, z-hypnotics are often prescribed for longer treatment periods [9] [10] [11] and sometimes in higher doses than recommended [10] . It is well known that long-term use of BZDs constitutes risk of abuse and dependence [9] . A few studies have presented information on the abuse liability of z-hypnotics [12] [13] [14] .
Hypnotic use in the elderly may be especially problematic and may induce serious adverse effects, in particular falls [15, 16] and cognitive impairment [17, 18] . Elderly patients should therefore be initiated with low doses of hypnotics. Comedication of z-hypnotics with other possibly addictive prescription drugs such as BZDs and opioids is not recommended and may increase the risk of adverse effects of z-hypnotics, especially in the elderly.
The use of z-hypnotics has increased worldwide, and in many countries, the z-hypnotics have now become the dominating agents for treatment of insomnia [9, 19, 20] . The prescribing patterns of hypnotics differ among countries, meaning that the 'main' prescribed hypnotic varies [9, 19, 21] . In the early 2000s, zolpidem was approximately twice as commonly prescribed as zopiclone, worldwide [21] . In Norway, zopiclone has been the dominant z-hypnotic since its introduction in 1994.
Our hypothesis was that the recommendation of short-term use of z-hypnotics as well as limiting the combined use with other medicines with abuse potential is not followed. We aimed to study use of z-hypnotics in the total adult population in Norway during 2007-2013, with focus on levels of recurrent use of z-hypnotics in new users in 2009 and treatment intensity as well as levels of co-medication with BZDs, opioids or both groups in the long-term recurrent users of z-hypnotics.
Materials and Methods
Study population. Our study included the total adult population (aged over 18 years) in Norway in the period of 2007-2013 who were registered with a valid personal identity number (around 4 million people).
Data source -NorPD. Since January 2004, all Norwegian pharmacies are obliged to send information on all dispensed prescriptions (reimbursed or non-reimbursed) electronically to the Norwegian Institute of Public Health for inclusion in the Norwegian Prescription Database (NorPD). The NorPD includes data on all individuals treated in ambulatory care and covers the entire population in Norway [22] . Data on medicines to patients treated in hospitals/ nursing homes are not available on patient level and hence not included.
The drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification system [23] . The following variables were retrieved from NorPD for each recorded dispensing: unique identity number (encrypted), sex and age of the patient, the date of dispensing and drug information (ATC code, defined daily dose (DDD), number of DDDs dispensed).
Data were retrieved for the period of 2007-2013 on all dispensed items of z-hypnotics (ATC group N05CF). The only z-hypnotics used in Norway in the study period were zopiclone (N05CF01) and zolpidem (N05CF02). In addition, data on BZDs and analgesic opioids were retrieved for use in the analyses related to co-medication. BZDs are used as anxiolytics (N05BA; diazepam, oxazepam, alprazolam), hypnotics (N05CD; nitrazepam, flunitrazepam and midazolam) or as anticonvulsive (N03AE01; clonazepam). All analgesic opioids (N02A) used in Norway were included: codeine (in combination with paracetamol), tramadol, dextropropoxyphene, morphine, oxycodone, fentanyl, buprenorphine and some others with low use. Although we used data measuring the volume of dispensed medicines, we assumed that it also reflects the use of medicines in the study population.
Analyses and statistics. All analyses were performed for the total study population (adults) and for the age groups of 18-39, 40-64 and 65+ years in both men and women.
Prevalence in use of z-hypnotics. Period prevalence (1 year) for the use of z-hypnotics in the years 2007-2013 was estimated by identifying the number of individuals who had dispensed at least one z-hypnotic during the actual year, and calculating the percentage of users in the adult population. The total number of inhabitants for the various age groups in Norway per 1 January in the studied years was retrieved from Statistics Norway.
New and recurrent users of z-hypnotics. New (incident) users of z-hypnotics in 2009 were defined as individuals with no filling of z-hypnotics during a 730-day (2 years) washout period prior to the date z-hypnotics were dispensed the first time in 2009. Date of first dispensing was set as day 0 of follow-up. Follow-up periods of recurrent users of z-hypnotics were divided into four 365-day (1st to 4th year) periods during the years 2009-2013: 1-365, 366-739, 740-1095 and 1096-1490 days after the first filling, respectively. Incident users of zopiclone or zolpidem who were dispensed any zhypnotic during the 1st period of follow-up were defined as 1-year recurrent users. Those who were dispensed z-hypnotics both in the 1st and the 2nd period of follow-up were defined as 2-year recurrent users, etc. Those who were dispensed z-hypnotics at least once in all of the four periods (4-year recurrent users) are referred to as long-term recurrent users. The percentage of recurrent users among the new users of z-hypnotics was calculated according to the number of users alive at the end of the respective follow-up periods.
Treatment intensity. Treatment intensity was measured as mean, median and 10th, 25th, 75th, and 90th percentile values of the annual amount of z-hypnotics dispensed in number of DDDs per patient in the 2nd, 3rd and 4th year of follow-up by gender and age. All DDDs used in this study are assigned by WHO [23] . One DDD is 7.5 mg for zopiclone and 10 mg for zolpidem.
Co-medication. For the long-term recurrent users of z-hypnotics, we counted for each year of follow-up the number of users registered with fillings of BZDs (anxiolytics and hypnotics) and the number with opioids. Co-medication was measured according to age, gender and z-hypnotic treatment intensity by stratifying each age/gender group into three subgroups defined by the group's median and 90% quantile of DDDs dispensed. The proportion of zhypnotic users with co-medication in each subgroup was then calculated.
All analyses were done in R version 3.1.0 [24] .
Ethical considerations. This study was based on data from NorPD only, with encrypted patient identity numbers, and there was no demand of approval by an ethical committee.
Results

Prevalence in use of z-hypnotics during 2007-2013.
The total number of individuals older than 18 years who had z-hypnotics dispensed increased slightly from 2007 (N = 340,525) to 2013 (N = 354,571), while the proportion of users in the population was relatively stable at 9.3% and 8.9%, respectively. Almost twice as many women used z-hypnotics in 2013 compared with men, and the use was highest in the oldest age group ( fig. 1 ). The gender and age differences were unchanged in the study period. 
Treatment intensity.
In new users of z-hypnotics with 4-year, long-term recurrent use, the treatment intensity was high already in the second year with a mean annual amount of 199 DDDs per patient in men and 169 DDDs in women. The amount dispensed slightly increased to 220 DDDs for women and 193 DDDs for men in the 4th year of follow-up. The treatment intensity in DDDs measured as mean, median and 10th, 25th, 75th and 90th percentiles according to gender and age groups is shown as a box plot in fig. 2 . The interquartile differences were greatest in the youngest age group. The median numbers of DDDs per patient were highest among the elderly (65+) in both men and women. For nearly all age groups, the mean and median increased slightly during the periods of follow-up. The 90th percentiles were highest in the youngest age group (18-39 years) for women and the middle age group (40-64 years) for men, and increased over time among the two younger groups.
Co-medication.
Among the 4-year, long-term recurrent users of z-hypnotics in total, the mean proportion with co-medication was 29% for BZDs while 34% received opioids during the 4th year of follow-up. This level of co-medication was similar from the 1st year to 4th year of follow-up. The proportions of co-medication with BZDs were highest among the youngest age group in both women and men ( fig. 3A) and increased with treatment intensity of z-hypnotics in all age groups in both genders. The proportion was generally highest among women. The proportions of co-medication with BZDs ranged from 18% in the oldest age group for men with lowest treatment intensity to 64% in the youngest age group for women with the highest treatment intensity.
Similar trends with age and treatment intensity were observed for co-medication with opioids in women, whereas for men co-medication with opioids was most common in the 40-to 64-year age group (fig. 3B ). Co-medication with opioids was more common in women than in men in the youngest age group while the gender differences levelled off with age. The largest gender difference was observed for co-medication with both opioids and BZDs among the 18-to 39-yearolds ( fig. 3C ). In the highest treatment intensity group, the proportion who received both these drugs was almost twice as high for women as for men (46% versus 26%). The levels of co-medication were lowest in the oldest age group (65+) in both men and women with less variation between the treatment intensity levels compared with the younger groups. Overall, the levels of co-medication were highest among the youngest age groups and lowest in the 65+-year age group ( fig. 3A, B, C) .
Z-hypnotic users co-medicated with BZDs mainly had anxiolytics BZDs such as diazepam/oxazepam dispensed. Co-medication with BZDs mainly used as hypnotics such as nitrazepam/flunitrazepam was low. The proportions were highest in the youngest (18-39 years) with 4.0% in men and 3.3% in women. The corresponding proportions were 2.9% and 2.0% in the age group 39-64 years and 1.8% and 1.5% in those aged 65+ years.
The z-hypnotic users who were co-medicated with BZDs during the last year of follow-up received on average 143 DDDs of BZDs during the year. The median was 55 DDDs. For opioids, the corresponding values were 119 and 35 DDDs.
Sensitivity analysis.
Decreasing the washout period to 365 days when defining new users of z-hypnotics increased the number of new users from 92 911 to 130 936 and the proportion of fourth-year recurrent users from 16.8% to 20.9% compared with the 730-day (2 years) washout period used in our study. Using only 1 year as washout would include more prevalent users with intermittent use of z-hypnotics. Increasing the washout period to 1095 days (3 years) decreased the number of new users to 79,896 and the proportion of fourth-year recurrent users to 16.2%. With a 5-year washout period, the corresponding numbers were 68,655 and 15.7%. Thus, a population of 'true' new users (with no previous use of z-hypnotics) is difficult to obtain, but increasing the washout period from 1 to 2 years Fig. 3 . Proportion (%) of 4-year, long-term recurrent users of z-hypnotics with at least one dispensing of benzodiazepines (BZDs) (A), opioids (B) or both groups (C) in the last year of follow-up, stratified by age, gender (♂=men, ♀=women) and number of DDDs dispensed of z-hypnotics. In the legend, q50 and q90 denote the 50% and 90% quantiles. DDD=defined daily dose. changed the results more than a further increase from 2 to 5 years. Thus, a 2-year washout period was chosen.
Discussion
We found that the 1-year prevalence of z-hypnotic use in the adult population in Norway was relatively stable around 9% in the period of 2007-2013. Of the new users of z-hypnotics, 17% continued to use these medications every year in the 4-year follow-up periods. This percentage of recurrent users was similar in men and women but increased strongly with age. The annual amount of z-hypnotics dispensed was high during the entire follow-up period and increased slightly over time. The interquartile ranges of the amount used showed that the use of z-hypnotics had a skewed distribution in all age groups and the skewness was highest in the youngest age groups. Nearly one-third of the long-term users of z-hypnotics received co-medication with BZDs and one-third with opioids in the last year of follow-up. Co-medication with both opioids and BZDs was most common in the youngest age groups and in z-hypnotic patients with high treatment intensity.
Overall, the proportion of incident z-hypnotic users developing long-term use was lowest in the age group 18-39 years while the skewness in distribution of treatment intensity was highest in this group. Co-medication with opioids and BZD was also highest in the youngest age group. One reason for the observed age differences in the use of co-medications could be differences in comorbidity. Confounding by indication could therefore be one explanation for the observed differences. However, misuse or addiction in the heavy users could be another explanation.
Hypnotics have received much attention from authorities and researchers regarding proper use [25] [26] [27] . In Norway, policy measures have been made in recent years to update the national prescribing guidelines for potentially addictive medicines as well as introduction of new guidelines for use of opioids in the management of pain in patients with non-malignant chronic pain [28, 29] . More restrictions in order to reduce the risk of driving a vehicle under the influence of medicines that may impair driving have also been issued [30] . Research from Norway and other countries shows that the use of hypnotics often deviates from the general treatment recommendations [9, 10, 31] . There may be various reasons why guidelines are often not followed.
Physicians may prescribe z-hypnotics based on an experience of a persisting clinical effect in patients using z-hypnotics for a longer time than the recommended short-term period. We found that quite a large proportion of the new z-hypnotic users continued treatment in all the 4 years of follow-up, which may indicate a prolonged clinical effect. Some other studies have documented that eszopiclone and zolpidem can maintain their effect for up to 12 months [7, 8] . Tolerance has been reported unlikely for both drugs [7, 8, 32] . On the other hand, other studies have found evidence that chronic use of zopiclone in the elderly is linked to adverse effects [31] .
Doctors may also choose not to follow the guidelines because z-hypnotics are considered to be harmless. Due to a short elimination time, the risk of residual effects the next day is considered low, and the abuse liability has been considered lower for z-hypnotics than for BZDs [21, 33] . However, a few reports concerning abuse of zopiclone or zolpidem confirm that there is a certain risk of abuse at least among people with a history of drug or alcohol abuse [34, 35] .
Despite the recommendations, we observed a high proportion of co-medication with benzodiazepines and opioids in recurrent users of z-hypnotics. This co-medication was expected based on earlier research, and can be explained by a common comorbidity of insomnia and anxiety [36] or insomnia and chronic pain [37, 38] . Combined use of z-hypnotics with BZD and opioids may produce additive CNS depressing effects and increase the risk of adverse effects. This is particularly worrying for the elderly who may be especially sensitive to harmful adverse effects [17, 18, 39] . The high degree of comedication with other prescription drugs with abuse potential may point in the direction that z-hypnotics have an abuse potential.
The higher prevalence among women and in the older age group is probably related to a higher prevalence of insomnia among females compared with men [40] , and among the elderly compared with the younger people. As drug use in institutions is not captured in our study, it seems likely that our results underestimate the use of z-hypnotics among the elderly, meaning that the prevalence in the elderly is even higher.
Strengths and limitations.
The major strength of this study is that it was based on detailed information from the NorPD on all dispensed drugs in Norway over several years in a large population of new users of z-hypnotics, thus eliminating recall bias.
Validating studies in selected populations has shown that for medicines used occasionally, the self-reported use is under-reported while there is more consistency with registryreported drug use and self-reported use for medicines used chronically [41] .
The most important limitation is the uncertainty as to whether the dispensed drugs were actually used by the patients. This may overestimate the use in patients with few refills of zhypnotics during the years of follow-up. Only the date of dispensing is available in the NorPD. In our study, we retrieved all fillings during a year in order to minimize the problems of overestimation when using short follow-up periods. In the recurrent users of z-hypnotics, one may assume that the patients will not refill their prescriptions unless they use the medications. Most z-hypnotic users have to cover the expenses themselves, as reimbursement for hypnotics is only available for patients receiving palliative care or cancer treatment.
Another limitation is that we do not know whether the comedications are used in the same treatment periods as we have only the information that the medications are dispensed during the same year. A large proportion of the recurrent users of z-hypnotics, however, received relatively high amounts of z-hypnotics corresponding to daily use during nearly half of the year, and more than one dispensing of BZDs/opioids. Therefore, for those who received such high amounts of zhypnotics, the possibility of concurrent use is high.
Another limitation is that use of z-hypnotics in patients residing in institutions is not registered in the NorPD, and no information whether individuals are moved to institutions is available, resulting in an underestimation of drug use in the population. Because institutionalization increases with age, underestimation is most likely among the elderly. Figures from Norway indicate that 5% of the elderly over 65 years were living in institutions in 2011 [42] . In our study, the elderly above 65 years are presented as one group, as a more detailed stratification on age would have given higher underestimates for the oldest groups due to lack of data in this population.
In general, it is difficult to know the exact drug use pattern when using DDDs to measure amount used. A high number of DDDs over a period can either mean high doses taken intermittently or lower doses taken frequently. We find the use of high non-therapeutic doses of z-hypnotics less likely due to the relatively low number of reported z-hypnotic intoxications [43] and a non-existent illegal market for zopiclone in Norway [44] . On this background, we interpret our findings that it is most likely that z-hypnotic users take therapeutic doses on a regular basis.
Elderly patients are recommended to use lower doses of zhypnotics compared with younger adults. As our calculations of amounts used were based on the defined daily doses (DDDs) for the general population of adults, our results of high amounts used especially in the elderly may indicate regular use in even longer periods. Women aged 65+ years used a mean amount of 202 DDDs per year during the fourth year of follow-up. If instead we assume that the elderly women used the recommended daily dose of 5 mg of zopiclone rather than 7.5 mg which is one DDD, this would correspond to approximately 300 days of treatment during a year. This may further indicate regular use among the elderly. All the tablet strengths of zopiclone/zolpidem have score lines making it possible to divide the tablets; thus, we chose not to include strength in the calculation of dose.
Our study shows that the use of z-hypnotics is relatively high in the adult Norwegian population and particularly in the elderly. New users of z-hypnotics continue to use medication for longer time periods than recommended in the guidelines. Neither z-hypnotics nor BZD hypnotics constitute the recommended therapy for primary or chronic insomnia. Cognitive therapy stands out as being the recommended treatment and should at least be taken into consideration for the elderly who are vulnerable to harmful side effects from hypnotics [40, 45] .
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